KBI Biopharma vs Novartis: CDMO Comparison
How does KBI Biopharma compare to Novartis for Gene Therapy manufacturing?
Side-by-side comparison of KBI Biopharma and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (15 vs 1) — a deeper regulatory paper trail.
- KBI Biopharma carries a cleaner inspection mix — no OAI classifications versus 2 for Novartis.
- Novartis holds 59 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
- Novartis has stronger MHRA / UK coverage (3 compliant certificates vs 1).
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both KBI Biopharma and Novartis qualify as Gene Therapy manufacturers; Novartis carries the higher composite Signal Score for Gene Therapy programs in this comparison.
What to evaluate for Gene Therapy programs
Both KBI Biopharma and Novartis qualify as Gene Therapy CDMOs. When choosing between them for Gene Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Frequently asked: KBI Biopharma vs Novartis
How does KBI Biopharma compare to Novartis for Gene Therapy manufacturing?
On CDMO Signal's composite Signal Score, KBI Biopharma is 84/100 and Novartis is 88/100; KBI Biopharma has 1 FDA inspection on record vs 15 for Novartis; European coverage is 1 active EMA+MHRA certificate for KBI Biopharma vs 62 for Novartis. Both are tracked in the CDMO Signal directory as Gene Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, KBI Biopharma or Novartis?
KBI Biopharma has 1 FDA inspection on record (NAI 0 / VAI 1 / OAI 0) and 0 warning letters. Novartis has 15 FDA inspections on record (NAI 6 / VAI 7 / OAI 2) and 0 warning letters.
How do KBI Biopharma and Novartis compare on European GMP coverage?
KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Novartis holds 59 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — KBI Biopharma or Novartis?
KBI Biopharma is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Gene Therapy manufacturing — KBI Biopharma or Novartis?
Both KBI Biopharma and Novartis are tagged as Gene Therapy CDMOs in our directory, so both are credible options for Gene Therapy programs. The most important differentiator for Gene Therapy selection is typically vector platform match: The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →